A Phase 1, Open-label, Dose Escalation and Dose Expansion Study for LNCB74, a B7-H4 Targeted Antibody Drug Conjugate, as Monotherapy in Participants With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LNCB 74 (Primary)
Indications Biliary cancer; Breast cancer; Endometrial cancer; Ovarian cancer; Solid tumours
Focus Adverse reactions
Sponsors NextCure

06 Mar 2025 According to a NextCure media release, cohort 1 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers completed in February 2025 and company is planning to initiate backfill cohorts in the second half of 2025.
10 Jan 2025 According to a NextCure media release, NextCure announced that the U.S. Food and Drug Administration had cleared its Investigational New Drug application for LNCB74.
10 Jan 2025 According to a NextCure media release, company announced the first patient has been dosed in this study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com